

Excellent Presentations at JSCO2015

Followings are the Excellent Presentations selected by the Program Committee from those presented at the 53rd Annual Meeting of the Japan Society of Clinical Oncology (JSCO2015).

Number of presentations awarded the Excellent Presentations

40 (including 8 Best Presentations)

Head and neck cancer

- Molecular surgical margin analysis and locoregional recurrence in head and neck cancer

Masamichi Hayashi (Nagoya univ; Johns Hopkins University)

Breast cancer

- Impact of tumor infiltrating lymphocytes as a predictive and prognostic factor in breast cancer patients with neoadjuvant chemotherapy

Daisuke Yotsumoto (Sagara Hospital)
- Prediction of the treatment response to neoadjuvant chemotherapy in breast cancer by subtypes using tumor-infiltrating lymphocytes

Shinichiro Kashiwagi (Osaka City University)

- Value of androgen receptor expression as a predictive factor of HER2-positive breast cancer

Aiko Nagayama (Tokyo Medical Center)

- Secondary cancer is an independent negative predictor of survival after breast conserving therapy

Kenshiro Shiraishi (The University of Tokyo hospital)

Lung cancer

- Mechanism of Acquired Resistance to ALK inhibitor, Alectinib in Lung Cancer

Harboring EML4-ALK Fusion Gene

Hideko Isozaki (Okayama University)

- De novo malignancies after lung transplantation

Fengshi Chen (Kyoto University)

Hepato-biliary-pancreatic cancers

- Identification of the recurrence related microRNAs from bone marrow in hepatocellular carcinoma patients

Keishi Sugimachi (Kyushu University Beppu Hospital; Fukuoka City Hospital)

- Incidence and risk factors for severe neutropenia during modified FOLFIRINOX therapy in patients with advanced pancreatic cancer

Ai Irisawa (National Cancer Center Hospital East)

Esophageal cancer

- Feasibility of tailoring neoadjuvant chemotherapy for patients with stage II/III squamous cell carcinoma of the esophagus

Toshiyasu Ojima (Wakayama Medical University)

Gastric cancer

- Neoadjuvant chemotherapy for gastric cancer: 2 courses or 4 courses? S-1/CDDP or paclitaxel/CDDP? **【Best Presentation】**

Takaki Yoshikawa (Kanagawa Cancer Center)

- Pre-planned feasibility and safety analyses of docetaxel/S-1 (DS) combination in a phase III study comparing DS vs S-1 as postoperative adjuvant chemotherapy for stage III gastric cancer (JACCRO GC-07) **【Best Presentation】**

Yoshihiro Kakeji (Kobe University)

- Spilling cancer cells into the peritoneal cavity during gastrointestinal reconstruction in gastric cancer surgery

Satoshi Murata (Shiga University of Medical Science)

Colorectal cancer

- Evaluation of first-line treatment for Metastatic colorectal cancer, Especially Resection of liver metastasis and Long survival, in Japanese Database (EMERaLD study) **【Best Presentation】**

Toshio Otsuji (Dongo Hospital)

- Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine (cape) in patients with stage III colon cancer (CC): Results of Japan Clinical Oncology Group study (JCOG0910) **【Best Presentation】**

Masayuki Ohue (Osaka Medical Center for Cancer and Cardiovascular Diseases)

- Relationship between ^{18}F -FDG accumulation and *KRAS* Mutation in Metastatic Colorectal Cancer

Kenji Kawada (Kyoto University)

- S-1 as adjuvant chemotherapy for stage III colon cancer: updated outcomes of ACTS-CC trial

Hitoshi OJIMA (Gunma Prefectural Cancer Center)

- Open Versus Laparoscopic Surgery For Advanced Low Rectal Cancer Patients - Japanese Multicenter Observational Study -

Ryosuke Okamura (Kyoto University Hospital; The Japan Society of Laparoscopic Colorectal Surgery)

- Propensity score-matched study to evaluate laparoscopic versus open surgery for advanced colorectal cancer

Toshihiro Nakao (The University of Tokushima)

- Predictive factors for regorafenib therapy in patients with refractory metastatic colorectal cancer

Azusa Komori (Aichi Cancer Center Hospital)

GIST

- Treatment choice and outcome for patients with metastatic/recurrent gastrointestinal stromal tumors indicated by the number of metastatic lesions and disease-free interval: Data from the Kinki GIST Registry

Shinsuke Sato (Shizuoka General Hospital)

Gynecologic cancers

- Establishment and analysis the useful findings on MRI for differential diagnosis between uterine leiomyomas and sarcomas

Ayako SUZUKI (Kinki University)

- Laparoscopic sentinel node navigated surgery for early endometrial cancer as a minimally invasive surgery

Tsuyoshi Yamashita (Hakodate Municipal Hospital)

- The effects of message framing on cervical cancer screening: a randomized controlled trial

Mai Ohashi (Jichi Medical University)

- Is Para-aortic lymphadenectomy an unnecessary procedure in surgical management for the patients with stage IB2, IIA2 and IIB cervical cancer? : Retrospective study of 308 cases.

Tetsushi Tsuruga (The University of Tokyo)

- Fractalkine system promotes ovarian cancer progression **【Best Presentation】**

Yuko Tanizaki (Wakayama Medical University)

Genitourinary cancer

- Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy

Yoshifumi Kadono (Kanazawa University)

- A phase III, multicenter, randomized, controlled study of combined androgen blockade with vs. without zoledronic acid in prostate cancer patients with metastatic

bone disease: results of ZAPCA trial

Tomomi Kamba (Kyoto University)

- The significance of peripheral circulating tumor cell clusters and gene analysis in the treatment of castration-resistant prostate cancer

Okegawa T (The University of Kyorin)

- Study of patient selection criteria for Active Surveillance for Low-Risk Prostate Cancer: From an interim analysis of PRIAS-JAPAN

Mikio Sugimoto (Kagawa University)

- Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world

Satoru Taguchi (The University of Tokyo)

- Targeting HER2 with T-DM1, an Antibody-cytotoxic Drug Conjugate, is effective in HER2-overexpressing bladder cancer

Hayashi T. (Hiroshima University; University of British Columbia)

Soft tissues sarcomas

- Final results of a randomized phase II study comparing trabectedin and best supportive care in patients with translocation-related sarcomas. **【Best**

Presentation]

Toru Hiruma (Kanagawa Cancer Center)

Precision medicine

- Identification of the irinotecan toxicity related variants by Exome analysis **[Best**

Presentation]

Ryouichi Tsunedomi (Yamaguchi University)

Management of adverse reaction

- The usefulness of Anti-HMGB-1 therapy for the Lipopolysaccharide-induced pulmonary dysfunction in radiation-primed mice **[Best Presentation]**

Risa Takahata (National Defense Medical College)

- NanoSuit®: a potential application for EGFR inhibitor-induced skin alteration

Satoshi Hirakawa (Hamamatsu University School of Medicine)

Patient Advocacy

- Information provisioning for cancer patients with sight impairment: Situations and issues just before "Act on the Elimination of Discrimination against the persons with disabilities" is enforced.

Chikako YAMAKI (National Cancer Center)

- Supporting for the work of cancer survivors

Yuko Takahara (Nagoya Daini Red Cross Hospital)